Esther Navarro-Illana1, Mónica López-Lacort2, Pedro Navarro-Illana1, Juan José Vilata3, Javier Diez-Domingo4. 1. Universidad Católica de Valencia 'San Vicente Mártir', C/ Espartero, 7, 46007 Valencia, Spain. 2. Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Avda. Catalunya 21, 46020 Valencia, Spain. 3. Hospital Universitario General, Casa de la Misericordia 12, 46014 Valencia, Spain. 4. Universidad Católica de Valencia 'San Vicente Mártir', C/ Espartero, 7, 46007 Valencia, Spain; Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Avda. Catalunya 21, 46020 Valencia, Spain. Electronic address: jdiezdomingo@gmail.com.
Abstract
OBJECTIVES: To assess the effectiveness of the HPV vaccines in preventing genital warts in young women. DESIGN: Population-based study using health databases. SETTING: Valencian Community (Spain). PARTICIPANTS: All girls and women aged 14-19years who were registered in the Valencian Community between January 2009 and December 2014 (n=279,787). MAIN OUTCOME MEASURES: Incident cases of genital warts were defined as the first activation of diagnosis code ICD-9-CM 078.11 (Condyloma acuminatum) in primary care and outpatient clinics during the study period. RESULTS: There were 612 cases of genital warts. The overall incidence rate was 75.8/100,000 person-years (95% CrI 69.7-81.8). There was a decrease in genital warts when female candidates to be vaccinated with quadrivalent HPV vaccine reached the age of 18 (in 2012), compared to previous years. Incidence of genital warts in unvaccinated women and those who received the bivalent vaccine was higher than in girls and women who received the quadrivalent HPV vaccine. The effectiveness of a three-dose regimen of the quadrivalent HPV vaccine was 77% (95 CrI: 66-85%), whereas that of a single dose was 61% (95 CrI: 20-87%). No effectiveness was seen with a full vaccination course with the bivalent HPV vaccine. CONCLUSIONS: Three doses of the quadrivalent HPV vaccine were effective against genital warts in our population. Moreover, with low vaccine coverage the incidence of genital warts decreased only in the vaccinated.
OBJECTIVES: To assess the effectiveness of the HPV vaccines in preventing genital warts in young women. DESIGN: Population-based study using health databases. SETTING: Valencian Community (Spain). PARTICIPANTS: All girls and women aged 14-19years who were registered in the Valencian Community between January 2009 and December 2014 (n=279,787). MAIN OUTCOME MEASURES: Incident cases of genital warts were defined as the first activation of diagnosis code ICD-9-CM 078.11 (Condyloma acuminatum) in primary care and outpatient clinics during the study period. RESULTS: There were 612 cases of genital warts. The overall incidence rate was 75.8/100,000 person-years (95% CrI 69.7-81.8). There was a decrease in genital warts when female candidates to be vaccinated with quadrivalent HPV vaccine reached the age of 18 (in 2012), compared to previous years. Incidence of genital warts in unvaccinated women and those who received the bivalent vaccine was higher than in girls and women who received the quadrivalent HPV vaccine. The effectiveness of a three-dose regimen of the quadrivalent HPV vaccine was 77% (95 CrI: 66-85%), whereas that of a single dose was 61% (95 CrI: 20-87%). No effectiveness was seen with a full vaccination course with the bivalent HPV vaccine. CONCLUSIONS: Three doses of the quadrivalent HPV vaccine were effective against genital warts in our population. Moreover, with low vaccine coverage the incidence of genital warts decreased only in the vaccinated.
Authors: Pam Sonnenberg; Clare Tanton; David Mesher; Eleanor King; Simon Beddows; Nigel Field; Catherine H Mercer; Kate Soldan; Anne M Johnson Journal: Sex Transm Infect Date: 2019-02-05 Impact factor: 3.519
Authors: Anita Lukács; Zsuzsanna Máté; Nelli Farkas; Alexandra Mikó; Judit Tenk; Péter Hegyi; Balázs Németh; László Márk Czumbel; Sadaeng Wuttapon; István Kiss; Zoltán Gyöngyi; Gábor Varga; Zoltán Rumbus; Andrea Szabó Journal: BMC Public Health Date: 2020-05-28 Impact factor: 3.295